NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Omeros Corporation OMER
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.05
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
USD -0.05
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-1.1%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -7.7M
Share of profit-0.0%
Consecutive raises—
Growth
+40.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+4.4%
+40.4%
+42.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+16.2%
Change, 10 years+88.4%
The share count grew 16% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 325.6M
total assets, end of FY2025
Total assetsUSD 325.6M
EquityUSD -121.2M
CashUSD 9.7M
Gross debtUSD 87.9M
Net debtUSD 78.2M
Current ratio2.76×
Net debt stands at -65% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
·
·
·
·
0.1
0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.2
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.2
−0.2
−0.2
−0.2
·
·
·
·
·
·
−0.1
−0.1
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.2
−0.1
0.0
0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.05
−2.70
−1.88
0.76
3.12
−2.41
−1.71
−2.61
−1.17
−1.65
−2.00
−2.22
−1.39
−1.59
−1.29
−1.37
−2.92
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−388.2
86.6
·
·
·
·
·
·
·
·
·
·
−382.8
−92.0
−48.9
Shares out B
0.07
0.06
0.06
0.06
0.06
0.06
0.05
0.05
0.05
0.04
0.04
0.03
0.03
0.03
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed